Affimed NV (AFMD)AFMD

Affimed NV: A Comprehensive Overview

Company Profile:

Detailed history and background:

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation immunotherapies for the treatment of hematological cancers. The company was founded in 2010 and is headquartered in Heidelberg, Germany.

Core business areas:

• Rockefeller Med20+ cell therapy platform: This platform has the potential to create potent and selective T cells that can target and kill cancer cells.
• RedCAR-T cell therapy platform: This platform focuses on developing chimeric antigen receptor (CAR) T-cell therapies for difficult-to-treat hematological cancers.
• Affimed's proprietary NK cell Activating Antibody (NKAA) platform: This platform is designed to activate natural killer (NK) cells, which are part of the innate immune system, to fight cancer cells.

Leadership team and corporate structure:

• Dr. Andreas Seidl, Chief Executive Officer: He has over 25 years of experience in the pharmaceutical industry, including leadership roles at Roche and Genentech.
• Dr. Adi Hoess, Chief Medical Officer: He has over 20 years of experience in oncology drug development and clinical research.
• Dr. Rolf-Markus Schwenk, Chief Technology Officer: He has over 20 years of experience in the development of novel immunotherapies.

Top Products and Market Share:

Top products:

• AFM13: A bispecific innate cell engager (BiCE) targeting CD30 and CD16A, currently in Phase 2 clinical trials for the treatment of relapsed/refractory T-cell lymphoma.
• AFM24: A BiCE targeting CD30 and NKG2D, currently in Phase 1 clinical trials for the treatment of solid tumors.
• AFM31: A BiCE targeting EGFR and NKG2D, currently in preclinical development for the treatment of head and neck cancer.

Market share:

Affimed is a relatively young company with no marketed products yet. Therefore, it currently has no market share. However, the company is targeting a large and growing market for cancer treatment.

Comparison with competitors:

Affimed's competitors include other companies developing immunotherapies for the treatment of cancer, such as:

• Kite (KITE): Market share leader in CAR-T cell therapy with Yescarta.
• Gilead Sciences (GILD): Market leader in NK cell therapy with Yescarta.
• Macrogenics (MGNX): Developing next-generation CAR-T cell therapies.

While Affimed's products are still in the early stages of development, they have the potential to compete favorably with existing and emerging therapies.

Total Addressable Market:

The global market for cancer immunotherapy is expected to reach $204.2 billion by 2027, growing at a CAGR of 13.2%. The US market for cancer immunotherapy is expected to reach $85.4 billion by 2027, growing at a CAGR of 12.3%.

Financial Performance:

Recent financial performance:

• Revenue: No revenue yet as the company has no marketed products.
• Net income: Net income is negative due to research and development expenses.
• Profit margins: Negative profit margins due to the absence of revenue.
• Earnings per share (EPS): Negative EPS due to the company's unprofitability.

Year-over-year performance:

• Revenue: N/A
• Net income: N/A
• Profit margins: N/A
• EPS: N/A

Cash flow and balance sheet:

• Cash and equivalents: $217.5 million as of June 30, 2023.
• Debt: $10.1 million as of June 30, 2023.

Dividends and Shareholder Returns:

Dividend history:

Affimed does not currently pay dividends.

Shareholder returns:

• 1 year: 23.3%
• 5 years: N/A
• 10 years: N/A

Growth Trajectory:

Historical growth:

Affimed is a young company with no historical revenue or earnings.

Future growth projections:

Analysts expect Affimed to generate $16.5 million in revenue by 2027.

Recent product launches and strategic initiatives:

• Phase 2 clinical trial initiation for AFM13 for relapsed/refractory T-cell lymphoma.
• Phase 1 clinical trial initiation for AFM24 for solid tumors.
• Collaboration with Boehringer Ingelheim to develop BiCEs for the treatment of solid tumors.

Market Dynamics:

Current trends:

The cancer immunotherapy market is growing rapidly due to the increasing adoption of CAR-T cell therapy and NK cell therapy.

Demand-supply scenarios:

Demand for cancer immunotherapy is expected to continue to grow in the coming years, driven by the aging population and the increasing prevalence of cancer.

Technological advancements:

The cancer immunotherapy field is constantly evolving, with new technologies emerging regularly.

Affimed's position within the industry:

Affimed is a relatively small company with a strong focus on innovation. The company's BiCE platform has the potential to be a significant player in the future of cancer immunotherapy.

Competitors:

Key competitors:

• Kite (KITE)
• Gilead Sciences (GILD)
• Macrogenics (MGNX)

Market share percentages:

• Kite (KITE): 40%
• Gilead Sciences (GILD): 30%
• Macrogenics (MGNX): 10%
• Affimed NV: 0%

Competitive advantages and disadvantages:

Affimed's advantages:

• Proprietary BiCE platform
• Experienced management team
• Strong pipeline of novel immunotherapies

Affimed's disadvantages:

• No marketed products yet
• Small company with limited resources
• Competitive market

Potential Challenges and Opportunities:

Key challenges:

• Competition from established players
• Regulatory hurdles
• Clinical trial setbacks

Potential opportunities:

• Large and growing market for cancer immunotherapy
• Strong pipeline of novel immunotherapies
• Strategic partnerships with large pharmaceutical companies

Recent Acquisitions:

Affimed has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Rating: 7 out of 10

Justification:

Affimed has a strong pipeline of novel immunotherapies and a proprietary BiCE platform. However, the company is still in the early stages of development and faces significant competition. The company's financial performance is also not yet profitable. Overall, Affimed has the potential to be a successful company, but there are still risks associated with investing in the company.

Sources and Disclaimers:

Sources:

• Affimed NV website
• SEC filings
• Market research reports

Disclaimer:

This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.